Literature DB >> 20688264

Astrocytes derived from fetal neural progenitor cells as a novel source for therapeutic adenosine delivery.

Annelies Van Dycke1, Robrecht Raedt, Alain Verstraete, Panos Theofilas, Wytse Wadman, Kristl Vonck, Detlev Boison, Paul Boon.   

Abstract

PURPOSE: Intracerebral delivery of anti-epileptic compounds represents a novel strategy for the treatment of refractory epilepsy. Adenosine is a possible candidate for local delivery based on its proven anti-epileptic effects. Neural stem cells constitute an ideal cell source for intracerebral transplantation and long-term drug delivery. In order to develop a cell-based system for the long-term delivery of adenosine, we isolated neural progenitor cells from adenosine kinase deficient mice (Adk(-/-)) and compared their differentiation potential and adenosine release properties with corresponding wild-type cells.
METHODS: Fetal neural progenitor cells were isolated from the brains of Adk(-/-) and C57BL/6 mice fetuses and expanded in vitro. Before and after neural differentiation, supernatants were collected and assayed for adenosine release using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
RESULTS: Adk(-/-) cells secreted significantly more adenosine compared to wild-type cells at any time point of differentiation. Undifferentiated Adk(-/-) cells secreted 137+/-5 ng adenosine per 10(5) cells during 24 h in culture, compared to 11+/-1 ng released from corresponding wild-type cells. Adenosine release was maintained after differentiation as differentiated Adk(-/-) cells continued to release significantly more adenosine per 24 h (47+/-1 ng per 10(5) cells) compared to wild-type cells (3+/-0.2 ng per 10(5) cells).
CONCLUSIONS: Fetal neural progenitor cells isolated from Adk(-/-) mice--but not those from C57BL/6 mice--release amounts of adenosine considered to be of therapeutic relevance. 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20688264      PMCID: PMC2953799          DOI: 10.1016/j.seizure.2010.05.010

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  37 in total

Review 1.  Adenosine and suppression of seizures.

Authors:  T V Dunwiddie
Journal:  Adv Neurol       Date:  1999

2.  Continuous local intrahippocampal delivery of adenosine reduces seizure frequency in rats with spontaneous seizures.

Authors:  Annelies Van Dycke; Robrecht Raedt; Ine Dauwe; Tom Sante; Tine Wyckhuys; Alfred Meurs; Kristl Vonck; Wytse Wadman; Paul Boon
Journal:  Epilepsia       Date:  2010-08-17       Impact factor: 5.864

Review 3.  The epidemiology of epilepsy in Europe - a systematic review.

Authors:  L Forsgren; E Beghi; A Oun; M Sillanpää
Journal:  Eur J Neurol       Date:  2005-04       Impact factor: 6.089

Review 4.  Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies.

Authors:  Detlev Boison
Journal:  Epilepsy Res       Date:  2009-05-09       Impact factor: 3.045

Review 5.  Genetically engineered human neural stem cells for brain repair in neurological diseases.

Authors:  Seung U Kim
Journal:  Brain Dev       Date:  2007-02-15       Impact factor: 1.961

6.  Engineering embryonic stem cell derived glia for adenosine delivery.

Authors:  Denise E Fedele; Peter Koch; Louis Scheurer; Elizabeth M Simpson; Hanns Möhler; Oliver Brüstle; Detlev Boison
Journal:  Neurosci Lett       Date:  2004-11-11       Impact factor: 3.046

Review 7.  Focal treatment for refractory epilepsy: hope for the future?

Authors:  Karen E Nilsen; Hannah R Cock
Journal:  Brain Res Brain Res Rev       Date:  2004-03

Review 8.  Cell therapy in models for temporal lobe epilepsy.

Authors:  R Raedt; A Van Dycke; K Vonck; P Boon
Journal:  Seizure       Date:  2007-06-12       Impact factor: 3.184

Review 9.  Potential new methods for antiepileptic drug delivery.

Authors:  Robert S Fisher; Jet Ho
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 10.  Concise review: prospects of stem cell therapy for temporal lobe epilepsy.

Authors:  Ashok K Shetty; Bharathi Hattiangady
Journal:  Stem Cells       Date:  2007-06-28       Impact factor: 6.277

View more
  4 in total

Review 1.  Neurological disorders and the potential role for stem cells as a therapy.

Authors:  Paul R Sanberg; David J Eve; L Eduardo Cruz; Cesar V Borlongan
Journal:  Br Med Bull       Date:  2012-02-21       Impact factor: 4.291

2.  Adenosine production by brain cells.

Authors:  Edwin K Jackson; Shawn E Kotermanski; Elizabeth V Menshikova; Raghvendra K Dubey; Travis C Jackson; Patrick M Kochanek
Journal:  J Neurochem       Date:  2017-04-06       Impact factor: 5.372

Review 3.  Adenosine-associated delivery systems.

Authors:  Mehdi Kazemzadeh-Narbat; Nasim Annabi; Ali Tamayol; Rahmi Oklu; Amyl Ghanem; Ali Khademhosseini
Journal:  J Drug Target       Date:  2015       Impact factor: 5.121

4.  ASTROCYTES: EMERGING STARS IN LEUKODYSTROPHY PATHOGENESIS.

Authors:  Angela Lanciotti; Maria Stefania Brignone; Enrico Bertini; Tamara C Petrucci; Francesca Aloisi; Elena Ambrosini
Journal:  Transl Neurosci       Date:  2013-06-01       Impact factor: 1.757

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.